$RVPH
REVIVA PHARMACEUTICALS HOLDINGS, INC.

2021 Q4 Form 10-K Financial Statement

#000143774922006332 Filed on March 15, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.302M $5.253M $2.140M
YoY Change -39.15% 145.52%
% of Gross Profit
Research & Development $2.663M $4.852M $0.00
YoY Change 1543.77%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $590.00
YoY Change -100.0% -100.0%
% of Gross Profit
Operating Expenses $3.965M $10.10M $352.0K
YoY Change 1026.29% 315.03% 107.06%
Operating Profit -$10.10M
YoY Change 315.03%
Interest Expense $1.530K -$2.410K $3.800K
YoY Change -59.74% -100.17% -98.73%
% of Operating Profit
Other Income/Expense, Net $278.2K $1.591M
YoY Change -218.04%
Pretax Income -$3.685M -$8.516M -$348.2K
YoY Change 958.26% 125.13% -348.72%
Income Tax $0.00 $8.281K $800.00
% Of Pretax Income
Net Earnings -$3.685M -$8.522M -$348.2K
YoY Change 958.26% 125.24% -348.72%
Net Earnings / Revenue
Basic Earnings Per Share -$0.58
Diluted Earnings Per Share -$249.1K -$576.2K -$124.1K
COMMON SHARES
Basic Shares Outstanding 13.98M 14.79M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.69M $29.69M $36.60K
YoY Change 81014.59% 238.89% -71.85%
Cash & Equivalents $29.69M $8.760M
Short-Term Investments
Other Short-Term Assets $1.716M $1.716M $7.620K
YoY Change 22420.47% 94189.01% -61.9%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $31.40M $31.40M $44.21K
YoY Change 70933.7% 258.4% -70.53%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $34.65M
YoY Change -47.75%
Other Assets $1.820K
YoY Change
Total Long-Term Assets $1.00 $0.00 $8.718M
YoY Change -100.0% -6014.56%
TOTAL ASSETS
Total Short-Term Assets $31.40M $31.40M $44.21K
Total Long-Term Assets $1.00 $0.00 $8.718M
Total Assets $31.40M $31.40M $8.762M
YoY Change 258.4% 258.4% 336910.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $509.6K $509.6K $1.008M
YoY Change -49.45% -49.45% 348.93%
Accrued Expenses $1.835M $1.835M $324.7K
YoY Change 465.21% 465.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.345M $2.345M $1.333M
YoY Change 75.94% 75.94% 1232.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $1.975M
YoY Change -100.0%
Other Long-Term Liabilities $372.7K $372.7K $2.214M
YoY Change -83.16% -81.02% 0.17%
Total Long-Term Liabilities $372.7K $372.7K $4.189M
YoY Change -91.1% -81.02% 89.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.345M $2.345M $1.333M
Total Long-Term Liabilities $372.7K $372.7K $4.189M
Total Liabilities $2.718M $2.718M $3.297M
YoY Change -17.56% -17.56% -51.62%
SHAREHOLDERS EQUITY
Retained Earnings -$66.83M -$58.31M
YoY Change 14.61% 6.94%
Common Stock $1.443K $923.00
YoY Change 56.34% 49.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $28.69M $28.69M $5.466M
YoY Change
Total Liabilities & Shareholders Equity $31.40M $31.40M $8.762M
YoY Change 258.4% 258.4% 336910.69%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$3.685M -$8.522M -$348.2K
YoY Change 958.26% 125.24% -348.72%
Depreciation, Depletion And Amortization $0.00 $0.00 $590.00
YoY Change -100.0% -100.0%
Cash From Operating Activities -$3.902M -$10.67M -$210.8K
YoY Change 1751.47% 162.34% 163.45%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$204.0K
YoY Change
Cash From Investing Activities -$204.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $31.50M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 98.48K $31.60M 442.1K
YoY Change -77.73% 146.33%
NET CHANGE
Cash From Operating Activities -3.902M -$10.67M -210.8K
Cash From Investing Activities -204.0K
Cash From Financing Activities 98.48K $31.60M 442.1K
Net Change In Cash -3.804M $20.93M 27.31K
YoY Change -14027.76% 138.89% -134.14%
FREE CASH FLOW
Cash From Operating Activities -$3.902M -$10.67M -$210.8K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Auditor Location
AuditorLocation
San Ramon, California
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14433286
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14433286
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9231737
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9231737
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0 USD
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29687944 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8760462 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1716057 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1816 USD
CY2021Q4 us-gaap Assets
Assets
31404001 USD
CY2020Q4 us-gaap Assets
Assets
8762278 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
509583 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1008046 USD
CY2021Q4 rvph Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
1835228 USD
CY2020Q4 rvph Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
324697 USD
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001742927
CY2021 dei Entity Registrant Name
EntityRegistrantName
REVIVA PHARMACEUTICALS HOLDINGS, INC.
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2344811 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1332743 USD
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
372730 USD
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1963785 USD
CY2021Q4 us-gaap Liabilities
Liabilities
2717541 USD
CY2020Q4 us-gaap Liabilities
Liabilities
3296528 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1443 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
923 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
95516986 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
63774920 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66831969 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58310093 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
28686460 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5465750 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31404001 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8762278 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4851602 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
295150 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5252911 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2139501 USD
us-gaap Operating Expenses
OperatingExpenses
10104513 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
2434651 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10104513 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-2434651 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1591055 USD
CY2020 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0 USD
rvph Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
-2414 USD
CY2020 rvph Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
105183 USD
us-gaap Interest Expense
InterestExpense
-0 USD
CY2020 us-gaap Interest Expense
InterestExpense
1453120 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1588641 USD
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1347937 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8515872 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3782588 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6004 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800 USD
us-gaap Net Income Loss
NetIncomeLoss
-8521876 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-3783388 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.24
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14790843
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3061670
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-6811430 USD
CY2020 us-gaap Deferred Compensation Arrangement With Individual Fair Value Of Shares Issued
DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued
340932 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
961680 USD
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
8499343 USD
CY2020 rvph Adjustments To Additional Paid In Capital Reclassification Of Warrant Liability
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability
1185577 USD
CY2020 rvph Adjustments To Additional Paid In Capital Proceeds From Reverse Recapitalization
AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization
9375961 USD
CY2020 rvph Effect Of Reverse Recapitalization Net Of Costs Value
EffectOfReverseRecapitalizationNetOfCostsValue
-4302928 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-3783388 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5465750 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5465750 USD
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
31497463 USD
CY2021 rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
98481 USD
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
39929 USD
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
106713 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-8521876 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
28686460 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-8521876 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-3783388 USD
CY2021 us-gaap Depreciation
Depreciation
0 USD
CY2020 us-gaap Depreciation
Depreciation
591 USD
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1591055 USD
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1084052 USD
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
961680 USD
CY2021 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
39929 USD
CY2020 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
106713 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
CY2021 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
0 USD
CY2020 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-2330738 USD
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1714241 USD
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-0 USD
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-498463 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
775101 USD
CY2021 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
CY2020 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
CY2021 rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
1510531 USD
CY2020 rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-773922 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10668462 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4066624 USD
CY2021 rvph Proceeds From Issuance Of Common Stock For Deferred Compensation
ProceedsFromIssuanceOfCommonStockForDeferredCompensation
0 USD
CY2020 rvph Proceeds From Issuance Of Common Stock For Deferred Compensation
ProceedsFromIssuanceOfCommonStockForDeferredCompensation
340932 USD
CY2021 rvph Proceeds From Reverse Recapitalization
ProceedsFromReverseRecapitalization
0 USD
CY2020 rvph Proceeds From Reverse Recapitalization
ProceedsFromReverseRecapitalization
9375961 USD
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
31497463 USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
98481 USD
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2021 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3110000 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31595944 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12826893 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
20927482 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
8760269 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8760462 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
193 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29687944 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8760462 USD
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
2400 USD
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
800 USD
CY2021 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
327076 USD
CY2021 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
CY2020 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
6875088 USD
CY2021 rvph Payment Of Certain Deferred Costs
PaymentOfCertainDeferredCosts
0 USD
CY2020 rvph Payment Of Certain Deferred Costs
PaymentOfCertainDeferredCosts
1000000 USD
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Use of estimates</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are <em style="font: inherit;">not</em> limited to, valuation of intangible assets, depreciative and amortization useful lives, assumptions used to calculate the fair value of the contingent share consideration, stock-based compensation, beneficial conversion features, warrant values, deferred taxes and the assumptions used to calculate derivative liabilities. Actual results could differ materially from such estimates under different assumptions or circumstances.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Concentration of credit risk and other risks and uncertainties</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company’s cash are held in demand deposit form by <em style="font: inherit;">one</em> financial institution. The Company has <em style="font: inherit;">not</em> experienced any losses on its deposits of cash.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are <em style="font: inherit;">not</em> limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company’s operating results <em style="font: inherit;"> may </em>be materially affected by the foregoing factors.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
41708 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
41708 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 USD
CY2021 us-gaap Depreciation
Depreciation
0 USD
CY2020 us-gaap Depreciation
Depreciation
591 USD
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0 USD
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1788135 USD
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-794343 USD
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-58152 USD
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-114864 USD
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
8924 USD
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0 USD
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1414 USD
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-45 USD
CY2021 rvph Effective Income Tax Rate Reconciliation Warrant Expense Amount
EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount
-334122 USD
CY2020 rvph Effective Income Tax Rate Reconciliation Warrant Expense Amount
EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount
227651 USD
CY2021 rvph Effective Income Tax Rate Reconciliation Beneficial Conversion Feature Amount
EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount
0 USD
CY2020 rvph Effective Income Tax Rate Reconciliation Beneficial Conversion Feature Amount
EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount
201953 USD
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
5301 USD
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
19204 USD
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2173051 USD
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
461244 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8281 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11262916 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9177607 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
81911 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
10898 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
197508 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
237976 USD
CY2021Q4 rvph Deferred Tax Assets Property Plant And Equipment And Start Up Costs
DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts
2557 USD
CY2020Q4 rvph Deferred Tax Assets Property Plant And Equipment And Start Up Costs
DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts
3332 USD
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11544892 USD
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9429813 USD
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14433286
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
11000
CY2020Q3 us-gaap Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
38992
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11544892 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9429813 USD
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
106713 USD
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2115079 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0 USD
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9231737
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 USD
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
281397 USD
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
0 USD
CY2021 us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
0.0000 pure
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
112932
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.37
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
47461
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
65471
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.86
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
127427
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.14
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
192898
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.46
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
192898
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.46
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
192898
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M3D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
95803
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.46

Files In Submission

Name View Source Status
0001437749-22-006332-index-headers.html Edgar Link pending
0001437749-22-006332-index.html Edgar Link pending
0001437749-22-006332.txt Edgar Link pending
0001437749-22-006332-xbrl.zip Edgar Link pending
a1.jpg Edgar Link pending
ex_345157.htm Edgar Link pending
ex_345158.htm Edgar Link pending
ex_345159.htm Edgar Link pending
ex_346563.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rvph-20211231.xsd Edgar Link pending
rvph-20211231_cal.xml Edgar Link unprocessable
rvph-20211231_def.xml Edgar Link unprocessable
rvph-20211231_lab.xml Edgar Link unprocessable
rvph-20211231_pre.xml Edgar Link unprocessable
rvph20211231_10k.htm Edgar Link pending
rvph20211231_10kimg002.jpg Edgar Link pending
rvph20211231_10kimg003.jpg Edgar Link pending
rvph20211231_10kimg004.jpg Edgar Link pending
rvph20211231_10kimg005.jpg Edgar Link pending
rvph20211231_10kimg006.jpg Edgar Link pending
rvph20211231_10kimg007.jpg Edgar Link pending
rvph20211231_10kimg008.jpg Edgar Link pending
rvph20211231_10kimg009.jpg Edgar Link pending
rvph20211231_10kimg010.jpg Edgar Link pending
rvph20211231_10kimg011.jpg Edgar Link pending
rvph20211231_10kimg012.jpg Edgar Link pending
rvph20211231_10kimg013.jpg Edgar Link pending
rvph20211231_10kimg014.jpg Edgar Link pending
rvph20211231_10kimg015.jpg Edgar Link pending
rvph20211231_10kimg016.jpg Edgar Link pending
rvph20211231_10kimg017.jpg Edgar Link pending
rvph20211231_10kimg018.jpg Edgar Link pending
rvph20211231_10kimg019.jpg Edgar Link pending
rvph20211231_10kimg020.jpg Edgar Link pending
rvph20211231_10kimg021.jpg Edgar Link pending
rvph20211231_10kimg022.jpg Edgar Link pending
rvph20211231_10kimg023.gif Edgar Link pending
rvph20211231_10kimg024.jpg Edgar Link pending
rvph20211231_10kimg025.jpg Edgar Link pending
rvph20211231_10kimg026.jpg Edgar Link pending
rvph20211231_10kimg027.jpg Edgar Link pending
rvph20211231_10kimg028.jpg Edgar Link pending
rvph20211231_10kimg029.jpg Edgar Link pending
rvph20211231_10kimg030.gif Edgar Link pending
rvph20211231_10kimg031.gif Edgar Link pending
rvph20211231_10k_htm.xml Edgar Link completed
Show.js Edgar Link pending